ArticleAnnals of coloproctology2026
Preoperative neutrophil to lymphocyte ratio as a survival predictor in nonmetastatic colon cancer in a Latin America-based population.
Article in Annals of coloproctology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColon cancer represents a major global health challenge, with a steadily increasing incidence. Therefore, the identification of novel and easily accessible biomarkers in colon cancer is essential. Although the neutrophil to lymphocyte ratio (NLR) has emerged as a potential prognostic indicator in various malignancies, its applicability in colon cancer within Latin America remains unexplored. This study evaluated the association between preoperative NLR and overall survival (OS) and disease-free survival (DFS).
methodsWe conducted a retrospective cohort study at the gastroenterology department of Mexico's National Cancer Institute between 2008 and 2022. All patients with nonmetastatic colon cancer who underwent upfront surgery were screened for inclusion. The optimal NLR cutoff value was determined using X-tile software and receiver operating characteristic curve analysis. Prognostic factors were assessed using Cox proportional hazards regression models.
resultsA total of 522 patients were included in the analysis and categorized into high NLR (>3.0, n=230) and low NLR (≤3.0, n=292). High NLR was associated with worse 3- and 5-year OS compared with low NLR (89.9% vs. 97.5% and 84.8% vs. 94.8%, respectively) in both univariate (P<0.001) and multivariate analyses (hazard ratio [HR], 3.020; 95% confidence interval [CI], 1.638-5.570; P<0.001). High NLR was also associated with worse 3- and 5-year DFS compared with low NLR (74.2% vs. 86.5% and 72.4% vs. 82.9%, respectively) in univariate (P=0.002) and multivariate analyses (HR, 1.627; 95% CI, 1.106-2.392; P=0.013).
conclusionThis exploratory study highlights the prognostic relevance of NLR in nonmetastatic colon cancer and supports its utility for predicting OS and DFS in a Latin American population. As a readily available biomarker, NLR may be particularly useful in low-income settings. Further prospective studies are required to validate its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.